Dr. Paul Averback reports

NYMOX REPORTS VICTORY IN BAHAMAS LITIGATION AGAINST TERMINATED EX-EMPLOYEES COURT AWARDS COSTS AND DAMAGES

The Bahamas Supreme Court has issued a formal order officially putting an end to the Bahamas litigation brought by terminated ex-employees of Nymox Pharmaceutical Corp. The order also awards to Nymox its costs incurred in defending the ill-conceived lawsuit, as well as damages Nymox has suffered as a result of the litigation.

The court order states the following:

1. The interim injunction order is set aside;
2. The damages caused to the company shall be assessed by a registrar and paid by the claimants (the persons who filed the lawsuit);
3. The claimants shall pay the company's net costs for the entire action.

This is the first of more than one action by and between the company and Randall Lanham (former general counsel for Nymox), Chris Riley (former short-term chief financial officer), Richard Cutler (former external Counsel and member of board and their financial backers.

Dr. Paul Averback, the company chief executive officer, stated: "The malfeasances by these persons has been a costly and time-consuming distraction for our hard-working, diligent management and board, and our great supportive shareholders. We have much more important and more positive things to do. Our shareholders were not fooled by the transparent mischief initiated with these attempts to take control of company properties, which these individuals did not make, develop, own or even faintly or remotely understand on any adequate technical or business level. We are delighted to continue to celebrate the departure of these individuals after they were fired last year, and the court verdict is a positive further step forward. The amounts of expenses plus damages is in process, and we will report further when we have that exact information. A hands-down victory for Nymox and for our great shareholders."

Dr. Averback continued: "The company has two submissions under review for its Nymozarfex drug treatment for prostate enlargement. The company also has the drug in development for prostate cancer. We are very happy to report that the work of the company has proceeded methodically. We cannot guarantee things that we do not control. One thing we do control, and we can guarantee, is that our extended team gives 110 per cent and does the maximum -- we are working for our shareholders, and in their best interests."

About Nymox Pharmaceutical Corp.

Nymox is in the process of submitting applications for the approval to market the company's first in class drug Nymozarfex to treat the symptoms of benign prostatic hyperplasia (BPH). BPH is one of the most common conditions affecting middle aged and elderly men throughout the world. BPH can be devastating to men who suffer from the condition. Current treatments are associated with numerous intolerable side effects, including sexual problems, such as impotence and retrograde ejaculation. Medications for BPH have been associated with prostate cancer, depression, gynecomastia and other adverse effects. The majority of men stop taking the available medications due to these and other problems. Surgery is often needed for advanced BPH. Surgery is usually effective but it is not without risks, including the discomforts of surgery in general and possible side effects of BPH surgery specifically, such as permanent retrograde ejaculation for many patients.

We seek Safe Harbor.